123 related articles for article (PubMed ID: 16784943)
1. The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumours.
Hillel PG; van Beek EJ; Taylor C; Lorenz E; Bax ND; Prakash V; Tindale WB
Clin Radiol; 2006 Jul; 61(7):579-87. PubMed ID: 16784943
[TBL] [Abstract][Full Text] [Related]
2. Contribution of ¹¹¹In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours.
Sainz-Esteban A; Olmos R; González-Sagrado M; González ML; Ruiz MÁ; García-Talavera P; Gamazo C; Villanueva JG; Cobo A; de Luis D
Nucl Med Commun; 2015 Mar; 36(3):251-9. PubMed ID: 25369750
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
J Nucl Med; 2003 Mar; 44(3):359-68. PubMed ID: 12621001
[TBL] [Abstract][Full Text] [Related]
4. Significance of a Single-Time-Point Somatostatin Receptor SPECT/Multiphase CT Protocol in the Diagnostic Work-up of Gastroenteropancreatic Neuroendocrine Neoplasms.
Ruf J; von Wedel F; Furth C; Denecke T; Stelter L; Steffen IG; Schütte K; Arend J; Ulrich G; Klose S; Bornschein J; Apostolova I; Amthauer H
J Nucl Med; 2016 Feb; 57(2):180-5. PubMed ID: 26609177
[TBL] [Abstract][Full Text] [Related]
5. Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors.
Wong KK; Cahill JM; Frey KA; Avram AM
Acad Radiol; 2010 Mar; 17(3):291-7. PubMed ID: 19962915
[TBL] [Abstract][Full Text] [Related]
6. Re: The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumours in receptor imaging.
Adesanya O
Clin Radiol; 2007 Jan; 62(1):92; author reply 93. PubMed ID: 17145272
[No Abstract] [Full Text] [Related]
7. Comparison of single time-point [111-In] pentetreotide SPECT/CT with dual time-point imaging of neuroendocrine tumors.
Wong KK; Wynn EA; Myles J; Ackermann RJ; Frey KA; Avram AM
Clin Nucl Med; 2011 Jan; 36(1):25-31. PubMed ID: 21157203
[TBL] [Abstract][Full Text] [Related]
8. Prediction of clinical outcome in treated neuroendocrine tumours of carcinoid type using functional volumes on 111In-pentetreotide SPECT imaging.
Gopinath G; Ahmed A; Buscombe JR; Dickson JC; Caplin ME; Hilson AJ
Nucl Med Commun; 2004 Mar; 25(3):253-7. PubMed ID: 15094443
[TBL] [Abstract][Full Text] [Related]
9. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours.
Chiti A; Fanti S; Savelli G; Romeo A; Bellanova B; Rodari M; van Graafeiland BJ; Monetti N; Bombardieri E
Eur J Nucl Med; 1998 Oct; 25(10):1396-403. PubMed ID: 9818279
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a Correction Method for
Kanzaki T; Takahashi Y; Higuchi T; Zhang X; Mogi N; Suto T; Tsushima Y
J Nucl Med Technol; 2020 Dec; 48(4):326-330. PubMed ID: 32887762
[TBL] [Abstract][Full Text] [Related]
11. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours.
Krausz Y; Keidar Z; Kogan I; Even-Sapir E; Bar-Shalom R; Engel A; Rubinstein R; Sachs J; Bocher M; Agranovicz S; Chisin R; Israel O
Clin Endocrinol (Oxf); 2003 Nov; 59(5):565-73. PubMed ID: 14616879
[TBL] [Abstract][Full Text] [Related]
12. Single-photon emission computed tomography tracers in the diagnostics of neuroendocrine tumors.
Pepe G; Bombardieri E; Lorenzoni A; Chiti A
PET Clin; 2014 Jan; 9(1):11-26. PubMed ID: 25029930
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Corleto V; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
Int J Oncol; 2003 Dec; 23(6):1687-95. PubMed ID: 14612942
[TBL] [Abstract][Full Text] [Related]
14. Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS.
Kumbasar B; Kamel IR; Tekes A; Eng J; Fishman EK; Wahl RL
Abdom Imaging; 2004; 29(6):696-702. PubMed ID: 15162235
[TBL] [Abstract][Full Text] [Related]
15. 111In-Pentetreotide SPECT/CT in Pulmonary Carcinoid.
Chiaravalloti A; Spanu A; Danieli R; Dore F; Piras B; Falchi A; Tavolozza M; Madeddu G; Schillaci O
Anticancer Res; 2015 Jul; 35(7):4265-70. PubMed ID: 26124388
[TBL] [Abstract][Full Text] [Related]
16. Clinical usefulness of fusion of 131I SPECT and CT images in patients with differentiated thyroid carcinoma.
Yamamoto Y; Nishiyama Y; Monden T; Matsumura Y; Satoh K; Ohkawa M
J Nucl Med; 2003 Dec; 44(12):1905-10. PubMed ID: 14660715
[TBL] [Abstract][Full Text] [Related]
17. Impact of 111In-DTPA-octreotide SPECT/CT fusion images in the management of neuroendocrine tumours.
Castaldi P; Rufini V; Treglia G; Bruno I; Perotti G; Stifano G; Barbaro B; Giordano A
Radiol Med; 2008 Oct; 113(7):1056-67. PubMed ID: 18797822
[TBL] [Abstract][Full Text] [Related]
18. Influence of attenuation correction by integrated low-dose CT on somatostatin receptor SPECT.
Ruf J; Steffen I; Mehl S; Rosner C; Denecke T; Pape UF; Plotkin M; Amthauer H
Nucl Med Commun; 2007 Oct; 28(10):782-8. PubMed ID: 17728608
[TBL] [Abstract][Full Text] [Related]
19. Value of image fusion using single photon emission computed tomography with integrated low dose computed tomography in comparison with a retrospective voxel-based method in neuroendocrine tumours.
Amthauer H; Denecke T; Rohlfing T; Ruf J; Böhmig M; Gutberlet M; Plöckinger U; Felix R; Lemke AJ
Eur Radiol; 2005 Jul; 15(7):1456-62. PubMed ID: 15627182
[TBL] [Abstract][Full Text] [Related]
20. [111In-pentetreotide in the study of tumors expressing somatostatin receptors].
Mateos Fernández J; Pons Pons F; Fuster Pelfort D; Vidal-Sicart S; Lomeña Caballero F; Herranz García-Romero R
Rev Esp Med Nucl; 1999 Oct; 18(5):325-30. PubMed ID: 10562660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]